The Berry Consultants software team will be hosting its January FACTS webinar next Friday, January 19th at 11am EST to present the development plans for adding an ordinal endpoint option to the trial simulator.
Blog by: Kert Viele The FDA draft master protocol guidance is out https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-drug-and-biological-product-development Comments are due by February 22. Here are some preliminary thoughts and
Blog by: Kert Viele If you see a significant result in a manuscript, should you assume the result is biased? We often see discussions of
Join Dr. Cora Allen-Savietta of Berry Consultants presenting a platform trial in Parkinson’s disease on Oct 25.
Blog by: Joe Marion Forward: This post is about the continual reassessment method, a type of design used for phase I dose-finding studies, particularly in
Blog by: Kert Viele On Thursday, I will be moderating a panel session (PS3B, 9/28/2023, 4:15-5:30 p.m.) at the ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop
Berry Consultants is proud to sponsor next week’s ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop on September 27-29 hosted in Rockville, MD.
Blog by: Kert Viele Bayesians draw conclusions based on posterior probabilities and utilities. Once an experiment is complete, Bayesian draw the same conclusions with the
Live Zoom webinar sessions open to the public on “Introduction to Adaptive Trial Designs using FACTS” will be held this October and November.
Blog by: Kert Viele External or synthetic data aspires to shorten clinical trials, saving resources while maintaining scientific accuracy. Like any aspiration, external data may
© 2012-2025 All rights reserved - Berry Consultants